INVESTABOT
Equity Research
XNYS · PHARMACEUTICAL PREPARATIONS
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
TL;DR: Pfizer posted revenue of $16.6 billion for FQ3-2026, with net income attributable to Pfizer Inc. common shareholders of $3.24 billion and diluted EPS of $0.56 per share.
open-market Form 4 only - grants, exercises, tax withholding excluded
1 buyers - 0 unique sellers · 9 accumulating - 4 trimming - 0 unchanged
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| October 30, 2026 | Bourla Albert | Chairman & CEO | GRANT | 20 | $31 | ~$1K |
| October 15, 2026 | Bourla Albert | Chairman & CEO | GRANT | 20 | $29 | ~$1K |
| October 13, 2026 | Bourla Albert | Chairman & CEO | GRANT | 71 | $28 | ~$2K |
| September 30, 2026 | Bourla Albert | Chairman & CEO | GRANT | 21 | $29 | ~$1K |
| September 25, 2026 | Taraporevala Cyrus | — | GRANT | 1,307.99 | $29 | ~$37K |
| September 25, 2026 | Smith James C | — | GRANT | 1,569.59 | $29 | ~$45K |
| September 25, 2026 | Quincey James | — | GRANT | 1,351.59 | $29 | ~$39K |
| September 25, 2026 | Narayen Shantanu | — | GRANT | 1,743.98 | $29 | ~$50K |
| September 25, 2026 | Echevarria Joseph | — | GRANT | 1,613.19 | $29 | ~$46K |
| September 25, 2026 | Buckley Mortimer J | — | GRANT | 1,307.99 | $29 | ~$37K |
| September 15, 2026 | Bourla Albert | Chairman & CEO | GRANT | 22 | $28 | ~$1K |
| August 31, 2026 | Bourla Albert | Chairman & CEO | GRANT | 21 | $28 | ~$1K |
| August 14, 2026 | Bourla Albert | Chairman & CEO | GRANT | 22 | $27 | ~$1K |
| August 12, 2026 | Bourla Albert | Chairman & CEO | BUY | 38,000 | $26 | ~$1.0M |
| August 5, 2026 | Blaylock Ronald E | — | BUY | 39,231 | $25 | ~$1.0M |
| August 5, 2026 | Buckley Mortimer J | — | BUY | 37,632 | $26 | ~$1.0M |
| August 5, 2026 | Damico Jennifer B. | SVP & Controller | SELL | -3,278 | $25 | ~$83K |
| July 31, 2026 | Bourla Albert | Chairman & CEO | GRANT | 24 | $25 | ~$1K |
| July 15, 2026 | Bourla Albert | Chairman & CEO | GRANT | 24 | $25 | ~$1K |
| July 9, 2026 | Bourla Albert | Chairman & CEO | GRANT | 84 | $24 | ~$2K |
| Date | Insider | Title | Relationship | Shares | Filing |
|---|---|---|---|---|---|
| August 28, 2026 | — | — | — | — | SEC |
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| BlackRock | 498,257,550 | ~$14.0B | 1.1% | May 13, 2026 |
| Vanguard Group | 541,346,182 | ~$13.5B | — | January 29, 2026 |
| BlackRock | 529,670,433 | ~$12.8B | 6.3% | August 7, 2026 |
| BlackRock | 493,062,528 | ~$12.3B | — | February 12, 2026 |
| BlackRock | 424,378,020 | ~$11.9B | — | August 13, 2024 |
| State Street | 301,589,865 | ~$8.5B | 0.4% | May 15, 2026 |
| State Street | 300,445,164 | ~$7.5B | — | February 13, 2026 |
| State Street | 307,090,897 | ~$7.4B | 1.8% | August 7, 2026 |
| Morgan Stanley | 92,685,370 | ~$2.6B | 4.0% | May 15, 2026 |
| Morgan Stanley | 96,345,452 | ~$2.3B | 4.0% | August 13, 2026 |
| Morgan Stanley | 89,113,604 | ~$2.2B | — | May 27, 2026 |
| Goldman Sachs | 49,810,156 | ~$1.4B | 19.9% | May 15, 2026 |
| Goldman Sachs | 54,833,150 | ~$1.3B | 10.1% | August 14, 2026 |
| Goldman Sachs | 41,535,562 | ~$1.0B | — | March 25, 2026 |
| JP Morgan Chase | 33,081,842 | ~$918.7M | 19.6% | May 13, 2026 |
| Citadel Advisors | 34,350,976 | ~$855.3M | — | February 17, 2026 |
| Citadel Advisors | 28,405,865 | ~$797.6M | -17.3% | May 15, 2026 |
| Citadel Advisors | 32,709,586 | ~$787.6M | 15.2% | August 14, 2026 |
| JP Morgan Chase | 27,658,547 | ~$688.7M | — | February 11, 2026 |
| JP Morgan Chase | 25,798,144 | ~$628.7M | -22.0% | August 12, 2026 |